All In Biotech

Drug Trial Radar · NCT07444268

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of DSP-5336 Following a Single Oral Dose in Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Myeloproliferative Neoplasms

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Mar 26, 2026

Primary completion

Aug 11, 2026

Study completion Sep 4, 2026

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Conditions

  • Advanced Hematologic Malignancies

Interventions

  • DSP-5336Drug

    tablet

  • [14C]-DSP-5336Drug

    oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336Time frame: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
  2. Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336Time frame: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
  3. Total recovery of radioactivity in excreta balance as percentage of total radioactive dose of [14C]-DSP-5336Time frame: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
  4. Relative abundance (mean value) of [14C]-DSP-5336Time frame: 4 days, max 7 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of North Carolina

    Chapel Hill, North Carolina

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.